Ezetimibe has been studied in 228 papers since 2006: 25 trials and 95 observational studies in people, 3 in animals, 82 reviews; 160 in the past year. It is an approved medicine. The newest story, Nov 9, 2026: “Evolocumab linked to fewer deaths in high-risk adults”.
Ezetimibe extends lifespan in one SR-BI/apoE dKO mouse study; independent labs report human LDL lowering. An observational study links use with lower mortality in statin-treated people with type 2 diabetes versus statins alone, but a trial shows no clear mortality effect. Papers declare company ties; across all uses, many trials ended over a year ago without posted results.
53 findings in 33 papers from 2006 to 2026, 15 of them since July 2026
Independent labs found the same change in people. 27 independent labs in 13 countries; 300 trials, 128 about aging, 153 with no results posted.
“Ezetimibe reduced the incidence of the primary outcome (hazard ratio [HR], 0.66; 95% CI, 0.50-0.86; P=0.002).”
Humans: replicated by independent labs. Cells and mice: a single group. Worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
27 independent labs in 13 countries
1 finding against
300 trials, 128 about aging, 153 with no results posted
“In the Ezetimibe group, the median LDL-C level decreased from 1.96 (1.76–2.44) to 1.49 (1.36–1.79) mmol/L (p < 0.001), while in the Alirocumab group, it decreased from 2.35 (2.08–2.92) to 1.33 (1.09–1.70) mmol/L (p = 0.001).”
Ezetimibe decreases LDL cholesterol in monotherapy.
“The comparison of the two treatments in terms of percent lipid variations showed that BBR/P/RR was more effective than EZE in reducing TC, LDL-C and non-HDL-C levels, and showed a tendency to lower TG more than EZE.”
Ezetimibe is linked with lower LDL cholesterol in humans (added to background moderate-intensity statin therapy, compared with bempedoic acid) (greater LDL-C reduction than bempedoic acid; no values stated).
“Low-density lipoprotein cholesterol (LDL-C) reduction was greater with ezetimibe.”
Humansadded to background moderate-intensity statin therapy, compared with bempedoic acidn = 6,706
Ezetimibe increases PTPRS expression in human cells.
“In SOAT2‐only‐HepG2 cells, selected predictions were supported experimentally, including APOA2 induction and ezetimibe‐associated PTPRS upregulation.”
Ezetimibe showed no clear effect on lipoprotein in humans (Compared with control in pooled randomized controlled trials) (MD 1.20%; 95% CI −3.04 to 5.44).
“Ezetimibe showed no significant effect on Lp(a) (MD, 1.20%; 95% CI, –3.04 to 5.44).”
ReviewCompared with control in pooled randomized controlled trials
Ezetimibe is linked with higher LDL-C target achievement in humans (added to high-intensity statin at discharge vs statin monotherapy in LDL-PMF patients) (OR 6.17, 95% CI 2.78–13.71; 65% vs. 27% reached target).
“ezetimibe use was the strongest independent predictor of reaching the target (OR 6.17, 95% CI: 2.78–13.71; p < 0.001)”
Humansadded to high-intensity statin at discharge vs statin monotherapy in LDL-PMF patients3 monthsn = 211
Ezetimibe showed no clear effect on number of plaque vulnerability criteria in humans.
“Direct comparison of the changes between the groups revealed no statistically significant differences in the number of vulnerability criteria (p = 0.930), and no statistically significant between-group differences in the number of vulnerable plaques (p = 0.894).”
Ezetimibe showed no clear effect on new-onset diabetes in humans (combined with rosuvastatin 5 mg, compared with rosuvastatin 20 mg monotherapy) (5.1% versus 14.5%; P=0.065).
“New-onset diabetes did not differ significantly between groups (5.1% versus 14.5%; P=0.065)”
Human trialcombined with rosuvastatin 5 mg, compared with rosuvastatin 20 mg monotherapyrosuvastatin 5 mg/ezetimibe 10 mg6 monthsn = 318
Ezetimibe decreases IgG apoB-containing immune complexes in humans (added to high-intensity statin) (-17.5%).
“Significant reductions in IgG apoB-IC levels were observed following treatment with high-intensity statins, add-on ezetimibe and add-on PCSK9i (by 18.3%, 17.5% and 25.5%, respectively, all p < 0.05).”
Human trialadded to high-intensity statin3 monthsn = 31
Studies link ezetimibe with 16 measures, among them LDL-C target attainment, cancer-related mortality and cardiovascular events.
LDL-C target attainment
↑upin humans2OR 2.64–5.28
2 studies
Ezetimibe is associated with LDL-C target attainment in humans (OR 5.28; 95% CI 1.31-21.32).
“ezetimibe use in addition to high-intensity statin therapy at discharge (OR 5.28; 95% CI 1.31-21.32) were associated with LDL-C target attainment.”
HumansAdded to high-intensity statin therapy at discharge after a first acute coronary syndrome; multivariable modelMedian 5 weeks (IQR, 4-6)Both; 70.7% malesn = 82
Ezetimibe is linked with a lower risk of cancer-related mortality in humans (compared with statin monotherapy) (HR 0.85).
“ezetimibe-statin combination therapy was associated with a significantly lower risk of cancer (hazard ratio [HR], 0.89; P<0.001) and cancer-related mortality (HR, 0.85; P<0.001)”
Humanscompared with statin monotherapyezetimibe-statin combination therapyn = 669,036
Ezetimibe is associated with LDL cholesterol in humans (Change from baseline in statin-intolerant patients receiving GLP-1 receptor agonists) (18.0 mg/dL reduction from baseline; 104.1 to 86.1 mg/dL).
“mean LDL-C decreased to 86.1 mg/dL in the ezetimibe cohort (Absolute Reduction (AR) = 18.0 mg/dL)”
HumansChange from baseline in statin-intolerant patients receiving GLP-1 receptor agonists1 yearn = 748
Ezetimibe is associated with ≥30% LDL-C reduction in humans Among bempedoic acid users; multivariable-adjusted association (aOR 1.81, 95% CI 1.55–2.11).
“EZE use in the 30 days pre-index (aOR[CI 95% ]: 1.81 [1.55-2.11]) was associated with greater likelihood of achieving ≥30% LDL-C reduction.”
HumansAmong bempedoic acid users; multivariable-adjusted associationEzetimibe use in the 30 days pre-indexn = 3,204
Ezetimibe is linked with a higher risk of focal epilepsy, lesion negative in humans (genetically proxied NPC1L1 inhibition (Mendelian randomization)) (OR 1.08 (95% CI 1.06–1.09); P = 5.9 × 10-31).
“but increased risks of focal epilepsy (lesion negative, OR = 1.08; 95% CI: 1.06-1.09; P = 5.9 × 10-31)”
Ezetimibe is linked with a lower risk of generalized epilepsy with tonic-clonic seizures in humans (genetically proxied NPC1L1 inhibition (Mendelian randomization)) (OR 0.98 (95% CI 0.97–0.98); P = 1.2 × 10-34).
“Inhibition of Niemann-Pick C1-Like 1 corresponded to a lower risk of generalized epilepsy with tonic-clonic seizures (OR = 0.98; 95% CI: 0.97-0.98; P = 1.2 × 10-34)”
Ezetimibe lowers the risk of atherosclerotic cardiovascular disease events in humans (without statin therapy and without a history of coronary artery disease).
“supports the reduction in the risk of atherosclerotic cardiovascular disease (ASCVD) events with ezetimibe without statin therapy in persons aged ≥75 years”
Reviewwithout statin therapy and without a history of coronary artery disease
Ezetimibe is linked with a higher risk of amnesia in humans (ROR = 1.55, 95% CI 1.20-2.00).
“Ezetimibe showed a positive signal for "amnesia" (ROR = 1.55, 95% CI 1.20-2.00) but an inverse association against "memory impairment" (ROR = 0.50, 95% CI 0.37-0.69).”
3 companies: Berlin Pharmaceutical Industry, JW Pharmaceutical and Organon.
Companies
Berlin Pharmaceutical IndustryPhase 4hypercholesterolemia in high or very high cardiovascular risk patients rosuvastatin, ezetimibe, hypercholesterolemia, dyslipidemia, cardiovascular diseases, LDL cholesterol, rosuvastatin, ezetimibe, hypercholesterolemia, dyslipidemia, cardiovascular diseases, LDL cholesterol
Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.